10-K · May 19, 2026
Silexion Therapeutics reported a challenging fiscal year ending December 31, 2025, with a significant EPS loss of -1.40 in its recent Q4 results and no reported revenue, signaling difficulties in its revenue generation.…
Earnings analysis · 10-Q
SLXN earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt does not include the quarterly income statement, balance sheet, cash flow statement, segment results, or MD&A, so revenue, margins, EPS, liquidity, and free cash flow cannot be assessed.…
Read full summary
The provided 10-Q excerpt does not include the quarterly income statement, balance sheet, cash flow statement, segment results, or MD&A, so revenue, margins, EPS, liquidity, and free cash flow cannot be assessed. Controls were reported effective as of June 30, 2026, but the company faces material litigation over the $3.433 million sponsor promissory note and ongoing equity and warrant activity. No quantitative guidance was provided in the available filing text.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls remained effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no material change in internal control over financial reporting during the quarter.
-
Warrant exercise transaction completed
The company completed an induced warrant exercise transaction on May 18, 2026, involving issuance of ordinary shares and new warrants.
-
Authorized share capital expanded
The authorized share capital was increased to $2,146,500, representing 15,900,000 ordinary shares with a $0.135 par value, on July 21, 2026.
What to watch
-
Sponsor promissory note litigation
Moringa Sponsor filed a complaint on June 22, 2026, seeking repayment of the $3.433 million original principal amount of the A&R Sponsor Promissory Note plus damages; the company is preparing its defense.
-
Potential warrant dilution
The May 18, 2026 induced warrant exercise transaction included issuance of new warrants and placement-agent warrants, creating potential future equity dilution.
-
Significant equity restructuring
The company completed a 1-for-10 reverse share split on May 29, 2026, and subsequently increased authorized capital to 15,900,000 ordinary shares, reflecting substantial equity-structure changes.
Management's outlook
The provided 10-Q excerpt contains no quantitative revenue or EPS outlook. No explicit guidance was provided.
Earlier filings 4
10-Q · May 15, 2026
Silexion Therapeutics reported a substantial net loss of $2.7 million for Q1 2026, increasing 58.8% year-over-year. Operating expenses doubled primarily due to significant investments in research and development as they…
10-K · March 17, 2026
Silexion is a clinical-stage oncology biotech focused on silencing KRAS with siRNA; its lead candidate SIL204 uses an integrated intratumoral + subcutaneous regimen in combination with standard chemotherapy and is being…
10-Q · August 12, 2025
Silexion reported no revenue for the quarter and posted a larger net loss as operating expenses accelerated. The company materially improved liquidity via equity raises (public offering and warrant exercises) — cash and…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.